Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

This study is testing a drug called abemaciclib — which blocks proteins that help cancer cells divide — in people with advanced solid tumors (not breast cancer) that have specific genetic changes affecting a group of proteins called D-type cyclins or CDK4/CDK6. **You may be eligible if...** - You have an advanced solid tumor (other than breast cancer) that has not responded to standard treatments - Your tumor has a specific genetic change in cyclin D genes or CDK4/CDK6 amplification, confirmed by testing - You are well enough to participate and have adequate organ function **You may NOT be eligible if...** - You have breast cancer - Your tumor does not have the required genetic change - You have already received abemaciclib - You have severe heart, liver, or other organ problems Talk to your doctor to see if this trial is right for you.